Click the Why column to see why an item matched the search.
| Match | Type | Why |
|---|
| Alani, Rhoda | Person |
Why?
|
| Melanoma brain metastasis: overview of current management and emerging targeted therapies. | Academic Article |
Why?
|
| Stat3-targeted therapies overcome the acquired resistance to vemurafenib in melanomas. | Academic Article |
Why?
|
| Protein kinase Cd is a therapeutic target in malignant melanoma with NRAS mutation. | Academic Article |
Why?
|
| Association of antibiotic treatment with survival outcomes in treatment-naïve melanoma patients receiving immune checkpoint blockade. | Academic Article |
Why?
|
| MITF Expression Predicts Therapeutic Vulnerability to p300 Inhibition in Human Melanoma. | Academic Article |
Why?
|
| Therapeutic effects of autologous tumor-derived nanovesicles on melanoma growth and metastasis. | Academic Article |
Why?
|
| Tumor necrosis factor receptor superfamily member TROY is a novel melanoma biomarker and potential therapeutic target. | Academic Article |
Why?
|
| The Efficiency of Verteporfin as a Therapeutic Option in Pre-Clinical Models of Melanoma. | Academic Article |
Why?
|
| Therapeutic Inhibitors against Mutated BRAF and MEK for the Treatment of Metastatic Melanoma. | Academic Article |
Why?
|
| Epigenetic Regulation of Resistance to Targeted Therapies in Melanoma | Grant |
Why?
|
| Adjuvant therapy of cutaneous malignant melanoma: a critical review. | Academic Article |
Why?
|
| Surgical adjuvant therapy of malignant melanoma with corynebacterium parvum. | Academic Article |
Why?
|
| Combining suramin and a chimeric toxin directed to basic fibroblast growth factor receptors increases therapeutic efficacy against human melanoma in an animal model. | Academic Article |
Why?
|
| Phase II trial of doxil for patients with metastatic melanoma refractory to frontline therapy. | Academic Article |
Why?
|